Skip to main content

Table 3 Univariate and multivariate associations between patient characteristics and survival

From: Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC

Characteristic Progression-free survival Overall survival
HR (95% CI) P value HR (95% CI) P value
Univariate associations
 Sex (female vs male) 0.752 (0.274–2.062) 0.579 0.357 (0.049–2.593) 0.308
 Age (<  65 years vs ≥ 65 years) 0.690 (0.430–1.108) 0.125 0.880 (0.492–1.572) 0.880
 ECOG performance status (0–1 vs 2) 1.930 (1.189–3.132) 0.008 1.152 (0.608–2.184) 0.665
 Smoker (No vs others) 1.164 (0.662–2.045) 0.598 0.995 (0.496–1.997) 0.989
 Histology (Squamous carcinoma vs others) 1.035 (0.653–1.642) 0.882 0.673 (0.366–1.238) 0.202
 Stage
  IIIA vs IIIB 1.273 (0.655–2.476) 0.477 1.520 (0.624–3.705) 0.357
  IIIA vs IIIC 0.914 (0.496–1.683) 0.773 1.056 (0.458–2.438) 0.898
 Chemotherapy (concurrent vs sequent) 1.529 (0.905–2.584) 0.113 2.350 (1.185–4.663) 0.014
 GTV (cm3) 1.002 (1.000–1.004) 0.014 1.004 (1.002–1.006) <  0.001
 PTV (cm3) 1.002 (1.001–1.003) 0.002 1.002 (1.001–1.004) <  0.001
 BED (Gy) 1.033 (0.969–1.101) 0.323 1.076 (0.994–1.164) 0.069
 Baseline TLCs (cells/μL) 1.000 (0.999–1.000) 0.437 1.000 (0.999–1.001) 0.699
 Pre-RT TLCs (cells/μL) 1.000 (0.999–1.000) 0.197 1.000 (0.999–1.000) 0.603
 SL (Yes vs No) 0.524 (0.331–0.831) 0.006 0.460 (0.255–0.831) 0.010
 TLCs nadir (cells/μL) 0.999 (0.998–1.000) 0.012 0.999 (0.997–1.000) 0.013
 OTT (LTRT vs STRT) 0.671 (0.386–1.167) 0.158 0.519 (0.249–1.081) 0.080
 IMRT (vs 3DCRT) 1.489 (0.881–2.517) 0.137 1.629 (0.850–3.122) 0.141
 HT (vs 3DCRT) 1.072 (0.621–1.849) 0.803 0.987 (0.474–2.053) 0.972
Multivariate associations
 ECOG performance status (0–1 vs 2) 1.720 (1.052–2.811) 0.031 N/A N/A
 PTV (cm3) 1.002 (1000–1.003) 0.006 1.002 (1.001–1.004) < 0.001
 SL (Yes vs No) 0.544 (0.343–0.863) 0.010 0.463 (0.256–0.837) 0.011
  1. Abbreviations: HR Hazard ratio, CI confidence interval, ECOG Eastern Cooperative Oncology Group, GTV gross tumor volume, PTV planning target volume, BED biological effective dose, TLCs total peripheral lymphocyte counts, RT radiotherapy, SL severe lymphopenia, OTT overall treatment time, Heart V5 the percentage of total heart volume receiving at least 5 Gy, LTRT long-term radiotherapy, STRT short-term radiotherapy, 3DCRT 3D conformal radiotherapy, IMRT Intensity modulated radiotherapy, HT Helical Tomotherapy, N/A not available
  2. Note: Multivariate analysis includes sex, age, ECOG, and variables with a P values of ≤0.2 on univariate analysis